These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

153 related items for PubMed ID: 8645506

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. The effect of a low-protein diet and dietary supplementation of threonine on tyrosine and 2-(2-nitro-4-trifluoromethylbenzoyl) cyclohexane-1,3-dione-induced corneal lesions, the extent of tyrosinemia, and the activity of enzymes involved in tyrosine catabolism in the rat.
    Lock EA, Gaskin P, Ellis MK, Robinson M, Provan WM, Smith LL.
    Toxicol Appl Pharmacol; 1998 May; 150(1):125-32. PubMed ID: 9630461
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. NTBC and alkaptonuria.
    Anikster Y, Nyhan WL, Gahl WA.
    Am J Hum Genet; 1998 Sep; 63(3):920-1. PubMed ID: 9718357
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Promising new treatment for type I tyrosinemia.
    Heubi JE.
    J Pediatr Gastroenterol Nutr; 1993 Oct; 17(3):340-1. PubMed ID: 8271141
    [No Abstract] [Full Text] [Related]

  • 9. New treatment for tyrosinaemia.
    Lancet; 1992 Oct 03; 340(8823):822-3. PubMed ID: 1357248
    [No Abstract] [Full Text] [Related]

  • 10. Plasma antioxidant capacity in two cases of tyrosinaemia type 1: one case treated with NTBC.
    Bird S, Miller NJ, Collins JE, Rice-Evans CA.
    J Inherit Metab Dis; 1995 Oct 03; 18(2):123-6. PubMed ID: 7564225
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. D-serine-induced nephrotoxicity: possible interaction with tyrosine metabolism.
    Williams RE, Lock EA.
    Toxicology; 2004 Sep 01; 201(1-3):231-8. PubMed ID: 15297036
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Treatment of hereditary tyrosinaemia type I by inhibition of 4-hydroxyphenylpyruvate dioxygenase.
    Lindstedt S, Holme E, Lock EA, Hjalmarson O, Strandvik B.
    Lancet; 1992 Oct 03; 340(8823):813-7. PubMed ID: 1383656
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. In brief: Nitisinone (Orfadin) for hereditary tyrosinemia.
    Med Lett Drugs Ther; 2016 Oct 10; 58(1505):e132. PubMed ID: 27701365
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Predicting tyrosinaemia: a mathematical model of 4-hydroxyphenylpyruvate dioxygenase inhibition by nitisinone in rats.
    Ward JP, Dunster JL, Derks G, Mistry P, Salazar JD.
    Math Med Biol; 2017 Sep 01; 34(3):335-390. PubMed ID: 27305933
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.